×
About 59,186 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  27,027 results

Genetically determined telomere length and multiple myeloma risk and outcome.
https://doi.org/10.1038/s41408-021-00462-y 10.1038/ng.993 10.1111/j.1365-2141.2012.09047.x 10.1038/ng.2733 10.1038/leu.2011.352 10.1111/j.1365-2141.2012.09244.x 10.1111/j.1600-0609.2011.01700.x 10.1038/ng.2583 10.1038/ncomms8539 10.1038/ncomms10290 10.1111/bjh.13830 10.18632/oncotarget.10665 10.1111/bjh.15521 10.3390/genes9050226 10.1080/10428194.2018.1551536 10.1126/science.1170633 10.1038/nrg1656 10.1186/s13058-018-0955-5 10.1158/1055-9965.EPI-11-0005 10.1371/journal.pone.0020466 10.1002/ijc.29101 10.1158/1055-9965.EPI-14-0247 10.1001/jamaoncol.2017.2316 10.1093/neuonc/not240 10.1093/jnci/djt016 10.1002/ijc.28934 10.1007/s11684-016-0450-2 10.1111/bjh.14643 10.1016/j.exphem.2010.06.010 10.1093/eurheartj/ehn386 10.1007/s00439-015-1563-4 10.1038/s41386-018-0289-0 10.1038/s41390-019-0699-7 10.1038/ng.2528 10.1093/hmg/dds382 10.1073/pnas.0911494107 10.1002/ijc.31928 10.1093/jnci/dju267 10.1016/j.eururo.2017.07.015 10.1093/hmg/ddw027 10.18632/oncotarget.6468 10.1093/carcin/bgw037 10.1093/hmg/ddv252 10.1007/s10552-016-0800-z 10.1038/s41408-020-00356-5 10.1056/NEJMra1011442 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U 10.1200/JCO.2005.04.242 10.1002/gepi.21758 10.1093/ije/dyv080 10.1093/ije/dyw220 10.1101/gr.137323.112 10.1038/ng.2653 10.1002/ijc.29101
Blood Cancer Journal; Giaccherini M, Macauda A et. al.

Apr 15th, 2021 - Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including multiple myeloma (MM...

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratu...
https://doi.org/10.1001/jamaoncol.2021.0611
JAMA Oncology; Landgren O, Hultcrantz M et. al.

Apr 15th, 2021 - Recently, the benefit of adding daratumumab to the proteasome inhibitor-based, 3-drug combination of bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who underwent high-dose melphalan chemotherapy and ...

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple m...
https://doi.org/10.1007/s12185-021-03139-1 10.1182/blood.V128.22.5950.5950 10.1016/j.jval.2015.09.1129 10.1182/blood-2016-08-731885 10.1182/blood-2017-03-775122 10.1111/bjh.15946 10.1016/S2352-3026(19)30110-3 10.1038/sj.leu.2404284 10.1002/ajh.23731 10.1038/s41408-018-0102-7 10.1111/cas.12772 10.1016/S2352-3026(19)30109-7
International Journal of Hematology; Matsumoto M, Suzuki K et. al.

Apr 15th, 2021 - The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed or refractory multiple...

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free...
https://doi.org/10.1038/s41434-021-00254-w 10.1073/pnas.36.6.344 10.1186/1759-8753-1-25 10.1038/nmeth.1332 10.1016/S0092-8674(00)80436-5 10.1089/hum.2011.143 10.1038/mt.2010.2 10.2174/156652311797415827 10.1002/bies.201000027 10.1182/blood-2009-04-210427 10.2174/1566523215666150126121353 10.1016/j.gde.2018.06.003 10.1080/10409238.2017.1304354 10.1002/bies.202000136 10.1016/j.virusres.2007.10.005 10.1038/75568 10.1007/978-1-4939-3271-9_2 10.1038/sj.gt.3302570 10.1038/mt.2009.319 10.1016/j.ymthe.2003.11.024 10.1093/nar/gks643 10.1038/sj.mt.6300366 10.1089/hum.2007.099 10.1038/sj.mt.6300169 10.1016/j.trsl.2012.12.005 10.1038/mt.2016.11 10.1016/j.ymthe.2003.11.009 10.1016/S0065-2660(05)54009-4 10.1016/j.coph.2005.04.015 10.2174/156652306778520647 10.1093/hmg/ddr140 10.1016/j.tig.2017.08.008 10.1172/JCI86721 10.1172/JCI138473 10.1182/blood-2009-03-210005 10.1038/ng.343 10.1089/hum.2017.136 10.1038/leu.2016.180 10.1016/j.ymthe.2018.01.012 10.1038/s41587-019-0291-z 10.1038/mtna.2013.1 10.1038/sj.gt.3300540 10.1038/gt.2011.215 10.1006/jmbi.2000.4047 10.1111/j.1582-4934.2007.00038.x 10.1182/blood-2017-04-778423 10.1007/978-3-319-42934-2_3 10.1182/blood-2011-02-337360 10.1007/s00432-020-03323-6 10.1056/NEJMoa1817226 10.1182/blood.2019000050 10.1038/leu.2015.247 10.1158/1078-0432.CCR-07-4246 10.1182/blood-2007-08-107292 10.1093/nar/gkv1464 10.1016/j.immuni.2016.01.021 10.1159/000492146
Gene Therapy; Prommersberger S, Reiser M et. al.

Apr 13th, 2021 - Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product to treatment sites. A...

Reactivation of resolved hepatitis B after daratumumab for multiple myeloma.
https://doi.org/10.1093/cid/ciab302
Clinical Infectious Diseases : an Official Publication Of... Lee SK, Sung PS et. al.

Apr 13th, 2021 - The risk of reactivation of resolved HBV in HBsAg-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This i...

see more →

Guidelines  185 results

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 7th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological mali...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.

Dec 5th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or interme...

see more →

Drugs  259 results see all →

Clinicaltrials.gov  29,299 results

Genetically determined telomere length and multiple myeloma risk and outcome.
https://doi.org/10.1038/s41408-021-00462-y 10.1038/ng.993 10.1111/j.1365-2141.2012.09047.x 10.1038/ng.2733 10.1038/leu.2011.352 10.1111/j.1365-2141.2012.09244.x 10.1111/j.1600-0609.2011.01700.x 10.1038/ng.2583 10.1038/ncomms8539 10.1038/ncomms10290 10.1111/bjh.13830 10.18632/oncotarget.10665 10.1111/bjh.15521 10.3390/genes9050226 10.1080/10428194.2018.1551536 10.1126/science.1170633 10.1038/nrg1656 10.1186/s13058-018-0955-5 10.1158/1055-9965.EPI-11-0005 10.1371/journal.pone.0020466 10.1002/ijc.29101 10.1158/1055-9965.EPI-14-0247 10.1001/jamaoncol.2017.2316 10.1093/neuonc/not240 10.1093/jnci/djt016 10.1002/ijc.28934 10.1007/s11684-016-0450-2 10.1111/bjh.14643 10.1016/j.exphem.2010.06.010 10.1093/eurheartj/ehn386 10.1007/s00439-015-1563-4 10.1038/s41386-018-0289-0 10.1038/s41390-019-0699-7 10.1038/ng.2528 10.1093/hmg/dds382 10.1073/pnas.0911494107 10.1002/ijc.31928 10.1093/jnci/dju267 10.1016/j.eururo.2017.07.015 10.1093/hmg/ddw027 10.18632/oncotarget.6468 10.1093/carcin/bgw037 10.1093/hmg/ddv252 10.1007/s10552-016-0800-z 10.1038/s41408-020-00356-5 10.1056/NEJMra1011442 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U 10.1200/JCO.2005.04.242 10.1002/gepi.21758 10.1093/ije/dyv080 10.1093/ije/dyw220 10.1101/gr.137323.112 10.1038/ng.2653 10.1002/ijc.29101
Blood Cancer Journal; Giaccherini M, Macauda A et. al.

Apr 15th, 2021 - Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including multiple myeloma (MM...

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratu...
https://doi.org/10.1001/jamaoncol.2021.0611
JAMA Oncology; Landgren O, Hultcrantz M et. al.

Apr 15th, 2021 - Recently, the benefit of adding daratumumab to the proteasome inhibitor-based, 3-drug combination of bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who underwent high-dose melphalan chemotherapy and ...

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple m...
https://doi.org/10.1007/s12185-021-03139-1 10.1182/blood.V128.22.5950.5950 10.1016/j.jval.2015.09.1129 10.1182/blood-2016-08-731885 10.1182/blood-2017-03-775122 10.1111/bjh.15946 10.1016/S2352-3026(19)30110-3 10.1038/sj.leu.2404284 10.1002/ajh.23731 10.1038/s41408-018-0102-7 10.1111/cas.12772 10.1016/S2352-3026(19)30109-7
International Journal of Hematology; Matsumoto M, Suzuki K et. al.

Apr 15th, 2021 - The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed or refractory multiple...

Personalized Cancer Vaccine Shows Early Promise Across Tumor Types
https://www.medscape.com/viewarticle/949339

Apr 14th, 2021 - A personalized genomic cancer vaccine proved feasible to manufacture and was well tolerated in a phase 1 trial, according to researchers. The vaccine, PGV-001, was given to 13 patients with solid tumors or multiple myeloma who had a high risk of r...

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free...
https://doi.org/10.1038/s41434-021-00254-w 10.1073/pnas.36.6.344 10.1186/1759-8753-1-25 10.1038/nmeth.1332 10.1016/S0092-8674(00)80436-5 10.1089/hum.2011.143 10.1038/mt.2010.2 10.2174/156652311797415827 10.1002/bies.201000027 10.1182/blood-2009-04-210427 10.2174/1566523215666150126121353 10.1016/j.gde.2018.06.003 10.1080/10409238.2017.1304354 10.1002/bies.202000136 10.1016/j.virusres.2007.10.005 10.1038/75568 10.1007/978-1-4939-3271-9_2 10.1038/sj.gt.3302570 10.1038/mt.2009.319 10.1016/j.ymthe.2003.11.024 10.1093/nar/gks643 10.1038/sj.mt.6300366 10.1089/hum.2007.099 10.1038/sj.mt.6300169 10.1016/j.trsl.2012.12.005 10.1038/mt.2016.11 10.1016/j.ymthe.2003.11.009 10.1016/S0065-2660(05)54009-4 10.1016/j.coph.2005.04.015 10.2174/156652306778520647 10.1093/hmg/ddr140 10.1016/j.tig.2017.08.008 10.1172/JCI86721 10.1172/JCI138473 10.1182/blood-2009-03-210005 10.1038/ng.343 10.1089/hum.2017.136 10.1038/leu.2016.180 10.1016/j.ymthe.2018.01.012 10.1038/s41587-019-0291-z 10.1038/mtna.2013.1 10.1038/sj.gt.3300540 10.1038/gt.2011.215 10.1006/jmbi.2000.4047 10.1111/j.1582-4934.2007.00038.x 10.1182/blood-2017-04-778423 10.1007/978-3-319-42934-2_3 10.1182/blood-2011-02-337360 10.1007/s00432-020-03323-6 10.1056/NEJMoa1817226 10.1182/blood.2019000050 10.1038/leu.2015.247 10.1158/1078-0432.CCR-07-4246 10.1182/blood-2007-08-107292 10.1093/nar/gkv1464 10.1016/j.immuni.2016.01.021 10.1159/000492146
Gene Therapy; Prommersberger S, Reiser M et. al.

Apr 13th, 2021 - Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product to treatment sites. A...

see more →

News  2,379 results

Personalized Cancer Vaccine Shows Early Promise Across Tumor Types
https://www.medscape.com/viewarticle/949339

Apr 14th, 2021 - A personalized genomic cancer vaccine proved feasible to manufacture and was well tolerated in a phase 1 trial, according to researchers. The vaccine, PGV-001, was given to 13 patients with solid tumors or multiple myeloma who had a high risk of r...

Multiple Myeloma Clinical Practice Guidelines (EHA/ESMO, 2021)
https://reference.medscape.com/viewarticle/948408

Mar 31st, 2021 - Clinical guidelines on the management of multiple myeloma (MM) were published in February 2021 by the European Hematology Association and the European Society for Medical Oncology in HemaSphere.[1] Watchful waiting is recommended for patients with...

First CAR T-Cell Therapy for Multiple Myeloma: Abecma
https://www.medscape.com/viewarticle/948248

Mar 28th, 2021 - Chimeric antigen receptor (CAR) T-cell therapy, described as a "living drug," is now available for patients with relapsed/refractory multiple myeloma who have been treated with four or more prior lines of therapy. The US Food and Drug Administrati...

'Phenomenal' Results with CAR T-Cells in R/R Multiple Myeloma
https://www.medscape.com/viewarticle/946733

Mar 1st, 2021 - Patients with multiple myeloma that has continued to progress despite many lines of therapy have shown deep and durable responses to a new chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel (ide-cel, under development by Bristo...

NICE Draft Guidance Approves Lenalidomide as Maintenance Treatment for Multiple Myeloma
https://www.medscape.com/viewarticle/944919

Jan 28th, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending lenalidomide (Revlimid, Bristol-Myers Squibb) as first maintenance treatment after an autologous stem cell transplant for newly diagnosed multip...

see more →

Patient Education  37 results see all →